Equities

Psychemedics Corp

PMD:NAQ

Psychemedics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.33
  • Today's Change-0.020 / -0.85%
  • Shares traded1.19k
  • 1 Year change-48.33%
  • Beta0.7047
Data delayed at least 15 minutes, as of Jul 03 2024 16:12 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.

  • Revenue in USD (TTM)21.60m
  • Net income in USD-4.46m
  • Incorporated1986
  • Employees116.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Syra Health Corp6.08m-3.60m8.28m78.00--2.47--1.36-0.5946-0.59461.050.52241.77--10.1977,937.56-105.01---154.43--23.75---59.21-----83.830.0279---1.83---38.72------
Caremax Inc810.36m-644.67m8.94m1.45k--0.438--0.011-172.31-172.31216.425.360.9467--6.07558,871.80-75.32---114.67---0.1988---79.55-----1.840.9506--19.01---1,707.99------
Medical Care Technologies Inc.0.00-1.07m8.99m0.00---------553,570.10-553,570.100.00-389.230.00-------154.94-----------------1.46---------40.06------
Ontrak Inc12.89m-32.98m9.65m102.00--0.4162--0.7485-4.00-4.000.51150.48340.5001--18.37126,411.80-93.19-54.80-121.21-73.3768.4353.50-186.35-71.95---2.990.0707---12.20-3.4439.08--99.58--
US NeuroSurgical Holdings Inc0.00-1.02m9.71m2.00--20.08-----0.1156-0.11560.000.03590.00----0.00-47.81-14.62-130.00-19.89-------36.77---20.960.00------38.97------
NewGenIvf Group Ltd0.00-690.85k9.77m----0.2301-----0.1999-0.19990.004.190.00-------1.50---1.54--------------0.0944-------237.99------
Xcelerate Inc3.96m-296.19k9.95m1.00--7.15--2.51-0.0014-0.00140.01890.00321.516.133.90---11.334.24-49.19--71.7174.10-7.481.930.4797-0.82180.7237--6.6310.4317.00--174.06--
Clearday Inc7.54m-21.54m10.82m225.00------1.43-0.9722-0.99380.3147-1.700.3432--201.6333,524.13-77.04-71.37---342.36-----224.52-205.25---0.9413-----3.0594.7325.38---28.32--
Pacific Health Care Organization Inc5.72m834.22k11.26m30.0013.521.0212.921.970.06510.06510.44590.85950.4725--6.09190,503.306.907.297.427.8179.4282.7514.6013.28----0.00---2.00-3.7055.80-10.80-15.93--
Univec Inc-100.00bn-100.00bn12.62m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Psychemedics Corp.21.60m-4.46m13.53m116.00--2.15--0.6264-0.773-0.7733.741.081.49--5.44186,172.40-30.68-7.44-46.72-9.7038.5737.55-20.64-6.26---184.940.0353---12.45-12.33-283.21---33.32--
Novo Integrated Sciences Inc13.66m-12.08m14.26m127.00--0.5986--1.04-0.7517-0.75170.85841.250.38248.708.88107,543.60-33.86-29.43-43.28-35.6440.3539.59-88.55-110.250.4089-3.980.1305--7.117.1759.77---22.73--
Kindly MD Inc3.44m-1.72m14.61m23.00------4.25-0.3017-0.30170.6102-0.06423.602.65355.09149,447.40-180.27---705.32--94.61---50.01--0.3484-14.61-----0.488--36.34------
PharmChem Inc5.98m745.75k16.24m170.0022.776.8321.782.710.15350.15351.230.51172.0411.378.65--25.44--30.51--64.23--12.46--4.95--0.00--3.50---16.95------
Data as of Jul 03 2024. Currency figures normalised to Psychemedics Corp's reporting currency: US Dollar USD

Institutional shareholders

19.99%Per cent of shares held by top holders
HolderShares% Held
22NW LPas of 31 Mar 2024274.42k4.73%
Renaissance Technologies LLCas of 31 Mar 2024259.86k4.48%
The Vanguard Group, Inc.as of 31 Mar 2024251.28k4.33%
RBF Capital LLCas of 31 Mar 2024142.14k2.45%
BlackRock Fund Advisorsas of 31 Mar 202475.87k1.31%
Wedbush Securities, Inc. (Investment Management)as of 31 Mar 202450.44k0.87%
Geode Capital Management LLCas of 31 Mar 202437.21k0.64%
Dimensional Fund Advisors LPas of 31 Mar 202431.17k0.54%
SMP Asset Management LLCas of 31 Mar 202420.00k0.34%
Citadel Securities LLCas of 31 Mar 202417.96k0.31%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.